According to the WHO report (2008), the human papillomavirus (HPV) causes almost 100% of cervical cancer cases. There are more than 100 HPV genotypes currently reported, and HPV consists of circular double helix DNA with approx. 7,900 bps. Compared to the traditional Pap test, HPV genotyping has several advantages; 1) high accuracy in determining the existence of HPV virus, 2) genotyping of HPV viruses, 3) early diagnosis, 4) identification of patients harboring HPV with a high-risk type and 5) contribution to the prevention and therapy of cervical cancers at the end. The PANA RealTyper ™ HPV kit is an in vitro diagnostic reagent for human papillomavirus (HPV) genotyping using peptide nucleic acid (PNA) probes. This kit is an amplified DNA test for the qualitative detection of a total of 40 HPV genotypes in a real-time PCR (polymerase chain reaction) system. This kit provides genotyping information for 20 high-risk and 2 low-risk types by melting temperature (Tm) analysis. In addition, this kit also detects 18 other genotypes (without genotyping) in DNA samples from clinical samples.
The PANA RealTyperTM HPV kit is an in vitro diagnostic reagent for human papillomavirus (HPV) genotyping using peptide nucleic acid (PNA) probes. This kit is a DNA amplification test for the qualitative detection of a total of 40 HPV genotypes in a real-time PCR (polymerase chain reaction). This kit provides genotyping information for 20 high-risk and 2 low-risk types by temperature melting (Tm) analysis. In addition, this kit also detects 18 other genotypes (without genotyping) in DNA samples from clinical specimens.
